Abstract:Henry J Kanarek, &ast Drew Austin Saville Mutschelknaus &ast Kanarek Allergy, Asthma & Immunology, Leawood, KS, USA &astThese authors contributed equally to this work Correspondence: Henry J Kanarek, Tel +1 (913) 451-8555, Fax +1 (913) 327-8553, Email Hereditary angioedema (HAE) is a rare genetic disorder characterized by potentially life-threatening episodes of swelling. Most HAE cases are caused by deficient (type I) or dysfunctional (type II) C1-esterase inhibitor (C1-INH) protein. However, some patients present with a subtype of HAE that is associated with normal plasma levels of functional C1-INH protein and complement component 4 (HAE-nC1INH). Treatment of HAE-nC1INH is driven by clinical experience as robust clinical trial data to inform treatment decisions are lacking in this population. This retrospective case series assessed clinical features and treatment outcomes in 15 patients with HAE-nC1INH who initiated long-term prophylaxis with oral berotralstat 150 mg once daily as part of their disease management pathway. Most patients were female (93%), with a median age of 49 years. All patients experienced abdominal swelling attacks. On average, patients tried a mean of 4 different treatments for their HAE, including berotralstat. Although most patients associated prophylactic and on-demand medications that target the bradykinin pathway with improvements in the frequency and/or severity of attacks, treatment outcomes varied considerably between patients, highlighting the importance of a personalized approach to disease management. In this case series, berotralstat was an effective prophylactic treatment option in most patients with HAE-nC1INH. Further studies are required to demonstrate the potential efficacy, safety, and impact on quality of life of currently approved HAE therapies in patients with HAE-nC1INH. Keywords: hereditary angioedema, normal C1-esterase inhibitor, prophylaxis, berotralstat, lanadelumab, plasma-derived C1-esterase inhibitor, abortive therapy Patients with hereditary angioedema (HAE) experience unpredictable and potentially life-threatening recurrent episodes of swelling that generally affect the extremities, genitals, abdomen, larynx, and face. 1–3 Some patients present with a form of HAE with normal C1-inhibitor (HAE-nC1INH), which is associated with normal plasma levels of functional C1-inhibitor (C1-INH) protein and complement component 4 (C4). 3 Mutations in genes such as coagulation factor XII (FXII), plasminogen, angiopoietin 1, kininogen 1, heparan sulfate glucosamine 3-O-sulfotransferase-6, and myoferlin have been identified in several patients with HAE-nC1INH. Some of these genes are involved with the production of bradykinin. However, the prevalence and pathophysiology of the disease are less clear than in HAE with low serum level or functional deficiency in C1 inhibitor (HAE-C1INH), and the etiology of the disease remains unknown for many patients. 1,4–9 Additionally, HAE-nC1INH is more challenging to definitively diagnose than HAE-C1INH because diagnosis reliant on genetic testing only identifies a small subset of patients with the disease. 8,10 Additionally, these genetic tests are not readily available in all clinical practices. 1 Overall, the swelling attacks experienced by patients with HAE-nC1INH and patients with HAE-C1INH are similar, but subtle differences exist between them 1,7 Patients with HAE-nC1INH typically present with their first symptoms of disease in late adolescence to early adulthood, while the first symptoms of HAE-C1INH typically appear in childhood. 1,5,11 Furthermore, patients with symptomatic HAE-nC1INH are predominately female, with exposure to estrogens frequently linked to the onset and exacerbation of swelling attacks. 4,5,12–14 Edema of the face, tongue, and oropharynx have been documented more frequently in patients with HAE-nC1INH than in patients with HAE-C1INH. 1,6,7,15,16 A review of 57 French patients with confirmed FXII mutations indicated that 74% of patients experienced HAE attacks affecting the ear, nose, and throat, while 80% experienced abdominal attacks 13 despite some experts suggesting that patients with HAE-nC1INH typically have fewer abdominal symptoms. 1 The occurrence of non-specific presenting symptoms in patients with HAE-nC1INH often results in misdiagnosis, ongoing treatment with inappropriate therapy (ie, antihistamines, corticosteroids, adrenaline) and/or unnecessary procedures (ie, surgical intervention). 5,17–19 Furthermore, the absence of robust data from clinical trials evaluating HAE therapies in patients with HAE-nC1INH means that, once diagnosis is suspected, the treatment of this patient population is based on clinical expe -Abstract Truncated-

Plasma-derived C1 esterase inhibitor pharmacokinetics and safety in patients with hereditary angioedema

Safety of C1-esterase inhibitor in acute and prophylactic therapy of hereditary angioedema: findings from the ongoing international Berinert patient registry

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

Plasma-derived and recombinant C1 esterase inhibitor: Binding profiles and neuroprotective properties in brain ischemia/reperfusion injury

Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database

Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants

Prolonging the circulatory half-life of C1 esterase inhibitor via albumin fusion

Increased thromboinflammatory load in hereditary angioedema

Quantification of C1 inhibitor activity using a chromogenic automated assay: analytical and clinical performances

C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia

A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema

Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study

Clinical features and potential markers of disease in idiopathic non-histaminergic angioedema, a real-life study

CRISPR-Based Therapy for Hereditary Angioedema

Analysis of cold activation of the contact system in hereditary angioedema with normal C1 inhibitor

Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema

C1 inhibitor deficiency enhances contact pathway-mediated activation of coagulation and venous thrombosis

Deucrictibant for angioedema due to acquired C1-inhibitor deficiency: a randomized-controlled trial

Clinical Experience with Berotralstat in Patients with Hereditary Angioedema with Normal C1-Esterase Inhibitor: A Commented Case Series

Berotralstat in hereditary angioedema due to C1 inhibitor deficiency: first real-world evidence from a Canadian center

Normalization of C1 Inhibitor in a Patient with Hereditary Angioedema